Webinar presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications, 22 November 2021
Date
Last updated
Disclaimer
These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.
The Australian Government Department of Health (of which the TGA is a part) advises that (a) the presentation papers should not be relied upon in any way as representing a comprehensive description of regulatory requirements, and (b) cannot guarantee, and assumes no legal liability or responsibility for, the accuracy, currency or completeness of the information contained in the presentation paper.
Presentation
- Presented by: Petra Bismire, Thearapeutic Goods Administration
- Presented at: Online
- Presentation date: Monday 22 November 2021
- Presentation summary: Presentation explaining how medical practitioners can apply to access certain medicinal cannabis medicines via the Authorised Prescriber Established History of use pathway (no ethics committee approval required) and guide you through applying to prescribe 'unapproved' medicinal cannabis products by category of active ingredient.
Presentation: Medicinal cannabis - Changes to Special Access Scheme (SAS) and Authorised Prescriber applications (pdf,991kb)
Topics
-
Application for consent to import, supply or export unapproved medical devices that are non-compliant with the Essential Principles
An overview of the amended sponsor portal to include unapproved medical devices and provides guidance on how to apply for consent to import, supply or export medical devices that do not comply with the Essential Principles (EPs).